为了争取对可切除和不可切除的癌症患者进行治疗以改善任何有意义的患者预后，需要进行药物治疗。然而，传统的全身给药的临床效益往往不令人满意。尽管药物递送系统是可取的替代方法，但仍难以满足各种临床需求，这是因为难以编程药物释放的配置文件。在此，我们引入了一个名为"Hierarchical Multiple Polymers Immobilization (HMPI)"的微纳加工概念，并设计了基于可降解聚合物的分层微器件(Hierarchical Microdevices，HMDs)，可以预先编程任何所需的控制释放配置文件。根据胰腺癌和乳腺癌的一线药物治疗，分别实现了单一吉西他滨和阿霉素/紫杉醇的控制释放。建立了胰腺术后、乳腺术后和不可切除乳腺癌的临床前模型，并证明了设计的分层微器件对抑制肿瘤生长、复发和转移具有良好的耐受性和有效性。所提出的HMPI策略使我们能够创建可定制和高分辨率的分层微结构，以根据临床用药计划进行预先编程的控制释放，这可能为术后和不可切除肿瘤的控制提供有希望的替代治疗方法。本文受版权保护。版权所有，禁止转载。

Drug treatment is required for both resectable and unresectable cancers to strive for any meaningful patient outcomes improvement. However, the clinical benefit of receiving conventional systemic administrations is often less than satisfactory. Drug delivery systems are preferable substitutes but still fail to meet diverse clinical demands due to the difficulty in programming drug release profiles. Herein, we introduce a microfabrication concept, termed Hierarchical Multiple Polymers Immobilization (HMPI), and engineer biodegradable polymers-based hierarchical microdevices (HMDs) that can pre-program any desired controlled release profiles. Based on the first-line medication of pancreatic and breast cancer, controlled release of single gemcitabine and the doxorubicin/paclitaxel combination in situ for multiple courses was implemented, respectively. Preclinical models of postsurgical pancreatic, postsurgical breast, and unresectable breast cancer were established, and the designed hierarchical microdevices demonstrated well-tolerable and effective treatments for inhibiting tumor growth, recurrence, and metastasis. The proposed HMPI strategy allows us to create tailorable and high-resolution hierarchical microstructures for pre-programming controlled release according to clinical medication schedules, which may provide promising alternative treatments for postsurgical and unresectable tumor control. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.